请输入您要查询的百科知识：

　

词条 Draft:Verastem Oncology
释义

  1. History

  2. Pipeline

  3. References

  4. External links

{{AFC submission|d|corp|u=Oldoaklanddental|ns=118|decliner=SamHolt6|declinets=20190210185048|ts=20190131170949}} {{AFC submission|d|corp|u=Oldoaklanddental|ns=118|decliner=SamHolt6|declinets=20190131002215|small=yes|ts=20190130221025}} {{AFC submission|d|v|u=Oldoaklanddental|ns=118|decliner=AngusWOOF|declinets=20190130173753|reason2=corp|small=yes|ts=20190130173008}} {{AFC comment|1=Despite recent improvements, the topic remains a NCORP failure as noted in Verastem Oncology and my multiple reviewers. It should be noted the company continues to lack the level on in-depth coverage required for inclusion on Wikipedia, especially considering the topic does not derive undue notability (per NOTINHERITED) from the drugs it produces. SamHolt6 (talk) 18:50, 10 February 2019 (UTC)}}{{AFC comment|1=Noting also that a similar draft concerning this topic was deleted at Verastem Oncology. SamHolt6 (talk) 15:01, 31 January 2019 (UTC)}}{{AFC comment|1=NCORP failure; needs more coverage in reliable, in-depth sources. SamHolt6 (talk) 00:22, 31 January 2019 (UTC)}}{{AFC comment|1=Need more secondary sources that aren't press releases or passing mentions. AngusWOOF (bark • sniff) 17:37, 30 January 2019 (UTC)}}
{{COI|date=January 2019}}{{original research|date=January 2019}}{{Infobox company
| name = Verastem, Inc.
| logo = File:Verastem Oncology official company logo.png
| type = Public
| traded_as = {{unbulleted list|{{NASDAQ|VSTM}}|NASDAQ Biotechnology Index}}
| industry = Pharmaceutical Industry
| foundation = 2010
| location = Needham, Massachusetts, United States
| products =
| key_people = Robert M. Forrester (President and CEO)

Dan Paterson (COO)

Jonathan Pachter Ph.D. (CSO)[1]


| operating_income =
| net_income =
| assets =
| equity =
| num_employees = 100-200
| homepage = {{URL|https://www.verastem.com}}
| footnotes =
| intl =
}}Verastem Oncology (Verastem, Inc.) is an American pharmaceutical company that identifies, develops and commercializes medicines to treat certain cancers.[2] Headquartered and founded in Boston, Massachusetts, Verastem Oncology is a member of NASDAQ Biotechnology Index. [3]

History

Verastem was co-founded in 2010 by a biotechnology entrepreneur Christoph H. Westphal and a venture capitalist Michelle Dipp, who provided seed funding and initial office space in Cambridge, MA. Lab research conducted by three other co-founders, MIT biologists Robert F. Weinberg, Eric S. Lander and Piyush Gupta, laid the foundation for what became Verastem's focus of discovering and developing drugs to treat cancer by targeting cancer stem cells.[4][5]

Verastem Oncology raised $16 million in the initial Series A financing.[6] Subsequent rounds of financing were Series B with $32 million and Series C with $20 million.[7]

Westphal served as CEO and Chairman of the Board for Verastem Oncology from 2010 to 2013. Under his leadership, the company raised $55 million through an IPO in 2012.[8] Verastem's current President and CEO Robert Forrester has succeeded Christoph Westphal in 2013.[9]

Pipeline

The leading investigational drug for Verastem Oncology, defactinib (VS-6063), a small-molecule focal adhesion kinase (FAK) inhibitor designed to kill cancer stem cells, was studied for the treatment of Malignant Pleural Mesothelioma.[10] In October 2015, Verastem announced the premature termination of the company's late-stage clinical trial for defactinib in Malignant Pleural Mesothelioma after data analysis demonstrated the drug was not effective enough to continue clinical trials.[11][12] Phase II COMMAND trial was discontinued due to finding no significant differences in efficacy versus placebo.[13] Following the failure of its clinical study, the company had to cut 50% of its workforce.[14]

In November 2016, Verastem Oncology licensed global rights from Infinity Pharmaceuticals to duvelisib (IPI-145), a novel inhibitor of PI3K delta and gamma.[15] A deal between Infinity and Verastem included no upfront payment, a $6 million milestone payment for success in a Phase 3 trial in chronic lymphocytic leukemia, a $22 million payment for an FDA approval and royalties.[16] In April 2018, Verastem filed a New Drug Application (NDA) for duvelisib for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and accelerated approval for relapsed or refractory follicular lymphoma (FL). The results of the clinical study DUO were published in Blood Journal.[17]

Verastem Oncology received an FDA approval for duvelisib on September 24, 2018 as a treatment for adult patients with 3rd-line chronic lymphocytic leukemia/small lymphocytic lymphoma, and an accelerated approval as a 3rd-line treatment for follicular lymphoma, contingent on the results of a confirmatory trial.[18] The drug label carries a black box warning due to the risk of potentially fatal or serious toxicities: infections, diarrhea or colitis, cutaneous reactions and pneumonitis.[19]

References

1. ^[https://www.verastem.com/about-us/leadership/management-team/ "Management Team"]. Verastem. Retrieved 12 February 2019.
2. ^{{Cite news|url=https://www.nasdaq.com/symbol/vstm |title=Company Overview |work=NASDAQ |access-date=12 February 2019}}
3. ^{{Cite news|url=https://www.nasdaq.com/press-release/verastem-oncology-added-to-the-nasdaq-biotechnology-index-20181220-00240 |title=Verastem Oncology Added to NASDAQ Biotechnology Index® |access-date=15 January 2019}}
4. ^{{cite news|last1=Sadeghi-Nejad|first1=Nathan|title=Cancer Stem Cell Therapy: Real Or Just Hype?|url=https://www.forbes.com/sites/natesadeghi/2012/10/09/cancer-stem-cell-therapy-real-or-just-hype/#254d9fb52ad8|work=Forbes|date=10 October 2012}}
5. ^{{Cite news|url=http://archive.boston.com/business/healthcare/articles/2011/07/15/verastem_lands_32m_in_financing/|title=Verastem lands $32m in financing |date=15 July 2011}}
6. ^{{Cite news|last1=Timmerman|first1=Luke||title=Verastem, Founded by MIT Big Names, Raises $16M to Fight Cancer Stem Cells |url=https://www.xconomy.com/boston/2010/11/16/verastem-led-by-mit-big-names-raises-16m-to-fight-cancer-stem-cells/ |work=Xconomy|date=16 November 2010}}
7. ^{{Cite news|url=https://www.crunchbase.com/organization/verastem/funding_rounds/funding_rounds_list#section-funding-rounds |title=Funding Rounds |work=Crunchbase |access-date=12 February 2019}}
8. ^{{cite news|url=https://xconomy.com/boston/2012/01/26/verastem-bucks-the-trend-raises-55m-in-ipo/ |title=Verastem Bucks the Trend, Raises $55M in IPO |date=26 January 2012}}
9. ^{{Cite news|url=https://xconomy.com/boston/2013/06/06/verastem-switches-ceos-as-westphal-steps-into-chairman-role/ |title=Verastem Switches CEOs as Westphal Steps Into Chairman Role |date=6 June 2013}}
10. ^{{Cite news|url=https://pubchem.ncbi.nlm.nih.gov/compound/Defactinib |title=Compound Summary for CID 25117126 |work=National Center for Biotechnology Information |access-date=31 January 2019}}
11. ^{{Cite news|url=https://clinicaltrials.gov/ct2/show/NCT01870609 |title=Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma (COMMAND)|access-date=31 January 2019}}
12. ^{{cite news|last1=Dulaney|first1=Chelsey|title=Verastem to Wind Down Mesothelioma Study|url=https://www.wsj.com/articles/verastem-to-wind-down-mesothelioma-study-1443440875|work=Wall Street Journal|date=28 September 2015}}
13. ^{{cite news|last1=Meredith|first1=Nancy|title=Dashed Hopes in the Mesothelioma Community After COMMAND Trial Stops Enrollment|url=https://www.mesotheliomahelp.org/dashed-hopes-mesothelioma-community-command-trial-stops-enrollment-82794/|work=Mesothelioma Help|date=15 October 2015}}
14. ^{{Cite news|title=Westphal's Verastem slashes staff in the wake of a clinical trial flop |url=https://www.fiercebiotech.com/biotech/westphal-s-verastem-slashes-staff-wake-of-a-clinical-trial-flop |work=Fierce Biotech |date=15 October 2015}}
15. ^{{cite news|title=Verastem Licenses Infinity Cancer Candidate Duvelisib|url=https://www.genengnews.com/topics/translational-medicine/verastem-licenses-infinity-cancer-candidate-duvelisib/|work=Genetic Engineering and Biotechnology News|date=2 November 2016}}
16. ^{{cite news|last1=Fidler|first1=Ben|title=Verastem Takes a Low-Cost Flier on Infinity’s Blood Cancer Drug|url=http://www.xconomy.com/boston/2016/11/02/verastem-takes-a-low-cost-flier-on-infinitys-blood-cancer-drug/|work=Xconomy|date=2 November 2016}}
17. ^{{cite journal |last1=Flinn |first1=Ian |last2=O’Brien |first2=Susan |date=15 May 2017 |title=Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies |journal=Blood |volume=131 |issue=8 |pages=877–887 |pmid=29191916 |pmc=6033052 |doi=10.1182/blood-2017-05-786566 }}
18. ^{{cite news|title=Duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)|url=https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm621503.htm|work=FDA|date=24 September 2018}}
19. ^{{cite news|last1=Carroll|first1=John|title=Unwanted by AbbVie and Infinity, battered Verastem gets an OK for duvelisib and a second shot at success |url=https://endpts.com/unwanted-by-abbvie-and-infinity-verastem-gets-an-ok-for-duvelisib-and-a-second-shot-at-success/ |work=Endpoints News|date=24 September 2018}}

External links

{{portal|Companies}}
  • {{Official website|http://www.verastem.com/}}
Category:Pharmaceutical companies of the United StatesCategory:Companies listed on NASDAQCategory:Pharmaceutical companies established in 2010
随便看

　

开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。

　

Copyright © 2023 OENC.NET All Rights Reserved
京ICP备2021023879号 更新时间：2024/9/25 20:31:53